Bioxyne Archives | Page 2 of 5 | Cannabiz

‘Not a revenue grab’: Curaleaf International CEO maps out Australian expansion plan

by Adam Sheldon November 27, 2025December 2, 2025

Curaleaf International chief executive Juan Martinez has outlined the firm’s Australian expansion strategy, saying it is […]

News in brief: Legalise Cannabis ramps up criticism of Victorian government; MCA launches desktop guide for clinicians; Bioxyne secures A$1.7m for UK GMP facility

by Adam Sheldon November 17, 2025February 21, 2026

News in brief: Cann completes NAB settlement; Bioxyne releases GMP-certified MDMA capsules

by Adam Sheldon November 11, 2025February 21, 2026

Breathe Life Sciences launches Curaleaf medical inhalation device

by Adam Sheldon November 3, 2025November 3, 2025

Record revenue for Bioxyne but cash deficit rises after flower investment

by Steve Jones October 30, 2025November 3, 2025

Cannabis executive salaries: who earned what in FY25

by Adam Sheldon October 22, 2025October 22, 2025

News in brief: The Entourage Effect named AFR innovation finalist; Bioxyne lists in Germany; Nimbin to host medical cannabis symposium

by Steve Jones October 13, 2025February 21, 2026

‘It’s super exciting’ – Breathe Life Sciences secures ARTG listings for Dr Watson range

by Adam Sheldon October 9, 2025October 13, 2025

Trump CBD video sparks US stock rally – and hope among local firms

by Adam Sheldon October 1, 2025October 1, 2025

News in brief: Epsilon receives EU, UK GMP certificates; AGH raises $2.6m via placement; Zelira secures loan notes; Bioxyne’s $5m German order

by Steve Jones September 17, 2025February 21, 2026